Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
Contact information
Media contacts:
B
oehringer Ingelheim
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
press@boehringer-ingelheim.com
Linda Ruckel
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay+ to Launch in Saudi Arabia, Facilitating Cross-Border Mobile Payments for Local Merchants16.9.2025 09:20:00 EEST | Press release
The Saudi Central Bank (SAMA) and Ant International, a leading global digital payment, digitisation, and financial technology provider, will launch cross-border QR code payments between the Kingdom of Saudi Arabia’s (KSA) national payment scheme, mada, and Ant International’s global wallet gateway, Alipay+, during 2026 to drive digitisation and inclusive growth for local merchants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915420538/en/ “We are deeply honoured to support the ambitious goals of Vision 2030 and build on the strong digital infrastructure by SAMA to enhance payment connectivity and boost Saudi Arabia’s status as a global tourism hub,” said Douglas Feagin, President of Ant International. “Tourism is a powerful force for economic growth and cultural connectivity. Through such joint innovations across public and private sectors, we can unlock more opportunities and help local businesses and communities flou
Lazard Expands Nordic Operations With the Appointment of Jesper Jensen as Managing Director and CEO of Investment Banking for Denmark16.9.2025 09:05:00 EEST | Press release
Lazard, Inc. (NYSE: LAZ) announces the expansion of Nordic operations with the appointment of Jesper Jensen as Managing Director, Financial Advisory and CEO of Denmark and the establishment of Lazard’s new office in Denmark effective September 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915634949/en/ Jesper Jensen With more than 25 years of experience and a deep connectivity in the local market, Jesper Jensen will enable Lazard to advance its presence in the country and strengthen client relationships in the Nordics. In the region, he will work closely with Gustaf Slettengren and Victor Kastensson, based in Sweden. “Jesper’s appointment reflects our determination to grow and to better address clients’ needs in the Nordic region as well as our confidence in Denmark,” stated Jean-Louis Girodolle, Co-Head of European Investment banking. “With his deeply connected Danish relationships and Lazard’s global reach, we are
New Report by Cambridge Identifies Five Priorities to Prepare Students for a Changing World16.9.2025 09:05:00 EEST | Press release
A major new report from the International Education group at Cambridge University Press & Assessment (Cambridge) captures the voices of nearly 7,000 teachers and students across 150 countries. It offers a unique view of how students experience education today and the skills and attributes they think are important for a future being shaped rapidly by technological advance, climate pressures, and shifting global dynamics. The report, Navigating the future: Preparing learners to thrive in a changing world, draws on responses from 3,021 teachers and 3,840 students worldwide, alongside insights from experts in education, social science, psychology, technology, government, and policy. It explores how students and their teachers feel about students’ readiness for the future, the skills they value, and the challenges they perceive in developing them. Both groups see opportunities in digital technologies to enhance learning, but voice concerns about distraction and risks to critical thinking an
Ant International’s Alipay+ to become Official Payment Partner of the Laver Cup16.9.2025 08:24:00 EEST | Press release
Laver Cup and Alipay+, part of Ant International, a leading global digital payment, digitization and financial technology provider, today formally announce a new long-term strategic partnership which will begin at Laver Cup San Francisco 2025, to be held at the Chase Center from September 19-21. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915513539/en/ The unified global wallet gateway Alipay+, along with WorldFirst and Antom – which are operated by Ant International – will become the Official Payment Partner of the Laver Cup through 2029. Ant Group's flagship service Alipay, an all-in-one digital platform for daily services in China will also join Alipay+ in the partnership. Ant International, with its associated brands Alipay+, WorldFirst and Antom, and Ant Group’s Alipay will play an important role in supporting the Laver Cup to drive fanbase growth and engagement in the Asia-Pacific region via its digital payment p
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody16.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine. The antibody was generated using Biocytogen’s proprietary RenMice® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to addr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom